POLB.F logo

Poolbeg Pharma OTCPK:POLB.F Stock Report

Last Price

US$0.20

Market Cap

US$83.9m

7D

0%

1Y

n/a

Updated

29 May, 2024

Data

Company Financials +

POLB.F Stock Overview

Operates as a biopharmaceutical company, engages in the development and commercialization of medicines for unmet medical needs in the United Kingdom.

POLB.F fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Poolbeg Pharma PLC Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Poolbeg Pharma
Historical stock prices
Current Share PriceUK£0.20
52 Week HighUK£0.23
52 Week LowUK£0.11
Beta2.16
1 Month Change41.01%
3 Month Changen/a
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO96.00%

Recent News & Updates

Recent updates

Shareholder Returns

POLB.FUS PharmaceuticalsUS Market
7D0%-1.7%-0.6%
1Yn/a17.9%25.4%

Return vs Industry: Insufficient data to determine how POLB.F performed against the US Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how POLB.F performed against the US Market.

Price Volatility

Is POLB.F's price volatile compared to industry and market?
POLB.F volatility
POLB.F Average Weekly Movementn/a
Pharmaceuticals Industry Average Movement9.7%
Market Average Movement5.9%
10% most volatile stocks in US Market15.9%
10% least volatile stocks in US Market2.9%

Stable Share Price: POLB.F's share price has been volatile over the past 3 months.

Volatility Over Time: Insufficient data to determine POLB.F's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
202112Jeremy Skillingtonwww.poolbegpharma.com

Poolbeg Pharma PLC operates as a biopharmaceutical company, engages in the development and commercialization of medicines for unmet medical needs in the United Kingdom. It develops POLB 001, which is in phase 1 clinical study for cancer immunotherapy-induced cytokine release syndrome and severe influenza. The company is also developing oral encapsulated GLP-1R agonist for obesity and diabetes treatment; influenza and respiratory syncytial virus AI programme; POLB 002, an in­licensed first­in­class broad spectrum RNA­based immunotherapy for respiratory virus infections; and POLB 003, an intramuscular vaccine to prevent Melioidosis.

Poolbeg Pharma PLC Fundamentals Summary

How do Poolbeg Pharma's earnings and revenue compare to its market cap?
POLB.F fundamental statistics
Market capUS$83.90m
Earnings (TTM)-US$5.00m
Revenue (TTM)n/a

0.0x

P/S Ratio

-16.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
POLB.F income statement (TTM)
RevenueUK£0
Cost of RevenueUK£0
Gross ProfitUK£0
Other ExpensesUK£3.93m
Earnings-UK£3.93m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.0079
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did POLB.F perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.